GNRH (LHRH)Stimulation Test - For FSH and LH - 5 samples

The GnRH (LHRH) Stimulation Test for FSH and LH is a supervised dynamic endocrine test that evaluates how the pituitary gland responds to stimulation by gonadotropin-releasing hormone. GnRH is also called luteinizing hormone-releasing hormone, or LHRH. The test includes five timed blood samples used to measure changes in Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

GnRH is naturally produced by the hypothalamus, a region of the brain that regulates pituitary function. It signals the pituitary gland to release FSH and LH. These hormones act on the ovaries or testes and play essential roles in puberty, menstrual function, ovulation, testosterone production and sperm development.

During the test, a baseline blood sample is collected before a prescribed stimulating medicine is administered. Additional samples are then collected at specifically timed intervals to measure the FSH and LH response. The exact medicine, dose, route and five sampling times must follow the protocol prescribed by the endocrinologist and adopted by the testing facility.

This is not a routine single-sample fertility profile. It requires medical authorisation, timed collection, trained supervision and appropriate observation. Results should be interpreted by an endocrinologist using the patient's age, sex, pubertal stage, menstrual-cycle phase, clinical findings and the exact stimulation protocol.

Benefits of the Test

• Evaluates the pituitary gland's capacity to release FSH and LH after stimulation.
• Measures the hormone response across five timed blood samples.
• Supports evaluation of suspected early or delayed puberty.
• May help assess hypothalamic or pituitary causes of hypogonadism.
• Provides more information than a single baseline FSH and LH measurement in selected patients.
• May assist in differentiating pubertal from prepubertal response patterns.
• Supports investigation of low or inconclusive baseline gonadotropin results.
• May be used to assess suppression during treatment for central precocious puberty when specifically prescribed.
• Provides a response curve showing the timing and magnitude of FSH and LH release.

Why Doctors Recommend This Test

A doctor may recommend a GnRH stimulation test when baseline LH and FSH measurements do not provide enough information about pituitary and reproductive function. The test examines whether the pituitary gland can respond appropriately when directly stimulated.

One important use is the assessment of suspected central precocious puberty. This refers to activation of the normal brain-pituitary-reproductive pathway at an unusually early age. Signs may include early breast development, testicular enlargement, rapid growth or other pubertal changes. A stimulated LH and FSH pattern may help an endocrinologist determine whether central puberty activation has occurred.

The test may also be used when puberty is delayed. Delayed puberty can result from constitutional delay, chronic illness, nutritional factors, dysfunction of the ovaries or testes, or inadequate stimulation from the hypothalamus or pituitary gland. The response to GnRH may contribute to the distinction between some of these causes, but it is not interpreted alone.

In adults, testing may support evaluation of selected cases of hypogonadotropic hypogonadism, unexplained low FSH and LH, amenorrhoea or suspected pituitary dysfunction. It is not a routine first-line fertility test and is performed only when a specialist determines that a dynamic assessment is clinically useful.

Children receiving GnRH-analogue treatment for central precocious puberty may sometimes undergo a stimulation test to evaluate whether pituitary gonadotropin release is adequately suppressed. The medicine and protocol used for treatment monitoring may differ from those used for initial diagnosis.

The test may be assessed with clinical examination, growth pattern, Tanner pubertal stage, bone-age X-ray, estradiol or testosterone, thyroid testing and imaging. No stimulated LH or FSH value should be used as an independent diagnosis without considering these findings.

Preparation Before Test

This test must be scheduled in advance and performed according to the prescribing endocrinologist's protocol. Patients should bring the doctor's request containing the indication, stimulating medicine, dose, route and required sampling times. A five-sample protocol is not identical at every hospital or laboratory.

Fasting requirements vary between protocols. Some centres allow normal food and fluids, while others may request fasting or restrict food for a specified period. Follow only the preparation instructions provided for the scheduled test. Plain water may generally be allowed unless the medical team advises otherwise.

Tell the doctor about all prescribed medicines, non-prescription medicines, hormonal treatments, injections, vitamins and supplements. Estrogen, progesterone, hormonal contraception, testosterone, anabolic steroids, fertility medicines and GnRH analogues may affect FSH and LH response. Do not stop any treatment unless the prescribing doctor specifically instructs you to do so.

Inform the clinical team about pregnancy or possible pregnancy, breastfeeding, allergies, previous reactions to injections, bleeding disorders, fainting during blood collection and current illness. For females who menstruate, the cycle day may be relevant and should be recorded when requested.

Children should wear comfortable clothing that allows easy access to the arm. A local anaesthetic cream may sometimes be used before cannula placement if arranged by the clinical team. A parent or guardian should follow the facility's instructions about accompanying the child.

Arrive at the instructed time because every subsequent sample depends on accurate timing. Late arrival may require rescheduling. Patients should expect to remain at the facility throughout the procedure and observation period.

Test Procedure and Five Samples

A healthcare professional generally inserts an intravenous cannula into a vein in the hand or arm. The cannula allows several blood samples to be collected without performing a separate needle puncture for every sample. The patient may be asked to rest before the first collection.

The first sample is the baseline or time-zero sample. It measures FSH and LH before stimulation. The prescribed GnRH, LHRH or appropriate GnRH-analogue medicine is then administered according to the authorised protocol.

Four additional samples are collected at specified times, creating a total of five samples. Published protocols vary and may use intervals such as 15, 30, 45 and 60 minutes, or 30, 60, 90 and 120 minutes after stimulation. Some GnRH-analogue protocols use longer intervals. Focus Diagnostics must follow the exact times stated in the authorised local protocol rather than assuming a universal schedule.

Accurate labelling is essential. Each tube should identify whether it is the baseline sample or the relevant post-stimulation time point. A delayed, missed or incorrectly labelled collection can make the response curve unreliable and may require the procedure to be repeated.

FSH and LH are measured in each sample. The doctor evaluates the baseline values, peak concentrations, time of peak, magnitude of increase and relationship between the stimulated LH and FSH responses.

The complete procedure may take approximately one to three hours depending on the five-sample schedule and observation requirements. Patients should remain at the testing facility until the supervising professional confirms that the procedure is complete.

Normal Reporting Time

The complete GnRH or LHRH Stimulation Test report is generally available within 24 to 48 hours after all five samples have been collected and accepted by the laboratory. The report may display the FSH and LH values separately for every sampling time.

Turnaround time may vary according to the day of testing, immunoassay schedule, laboratory workload, quality-control procedures and the need to repeat a measurement. A complete report cannot be prepared until every timed sample has been processed and verified.

Clinical interpretation may take additional time because the result must be reviewed against the specific medicine, dose, protocol, age, sex and pubertal stage. Patients should discuss the report with the prescribing endocrinologist rather than interpreting an isolated peak value.

Who Should Take This Test?

This test may be prescribed for children showing physical signs of puberty earlier than expected. It may help investigate whether the hypothalamic-pituitary-gonadal pathway has become active. The doctor may also assess growth velocity, bone age, pubertal stage and sex-hormone concentrations.

Children or adolescents with delayed or absent pubertal development may also require testing. GnRH stimulation may provide information about pituitary gonadotropin reserve, although results can overlap between constitutional delay and some disorders. Specialist interpretation is essential.

Selected adults with very low or inconclusive baseline FSH and LH, suspected hypothalamic or pituitary dysfunction, unexplained amenorrhoea or hypogonadotropic hypogonadism may be considered for this test by an endocrinologist.

Patients receiving treatment for central precocious puberty may sometimes undergo stimulation testing to assess biochemical suppression. The timing of testing in relation to treatment injections and the stimulating agent must be specified by the treating specialist.

This test should not be booked as a routine fertility screening package without medical advice. Most initial fertility evaluations use baseline hormones, ovarian-reserve tests, ovulation assessment, semen analysis and reproductive imaging rather than a GnRH stimulation test.

Detailed Information

The hypothalamus normally releases GnRH in pulses. These pulses stimulate the anterior pituitary gland to secrete LH and FSH. In females, FSH supports ovarian follicle development, while LH participates in ovarian hormone production and ovulation. In males, FSH supports sperm development and LH stimulates testosterone production.

The stimulation test temporarily challenges this hormonal pathway. A measurable rise in LH and FSH indicates that the pituitary contains releasable gonadotropins and can respond to stimulation. The pattern expected in a prepubertal child differs from that expected during puberty or adulthood.

When central puberty has started, the stimulated response may become more LH-predominant. A more FSH-predominant response may be seen in prepubertal patterns or isolated premature breast development. However, response patterns overlap, and the LH-to-FSH relationship must not be used as the only diagnostic criterion.

A weak response may occur with pituitary dysfunction, long-standing hypothalamic suppression, delayed puberty or the influence of hormonal medicines. An increased response may be seen with primary ovarian or testicular failure and other clinical states. The meaning depends on baseline concentrations and the clinical situation.

Cut-off values are not universal. They vary with the stimulating medicine, dose, sampling time, assay sensitivity, age, sex and clinical purpose. A threshold established for one protocol must not automatically be applied to a different five-sample protocol or laboratory method.

The test does not directly assess ovarian reserve, egg quality, sperm count, uterine structure or reproductive anatomy. Additional investigations may include estradiol, testosterone, AMH, prolactin, thyroid tests, bone-age assessment, pelvic or testicular ultrasound, pituitary imaging or genetic testing.

GnRH or LHRH is generally well tolerated when administered under supervision. Temporary flushing, headache, nausea, dizziness, abdominal discomfort or injection-site symptoms may occur. Blood collection may cause brief pain, bruising or faintness. Any unusual symptom during the procedure should be reported immediately to the supervising healthcare professional.

The patient should not independently purchase or administer the stimulating medicine. Because this is a supervised dynamic test involving prescribed medication and precisely timed samples, it must be conducted only through an appropriately equipped medical facility.